Author:
Nehru Vijayalakshmi Jawaharlal,Jose Vandakunnel Maria,Brammacharry Usharani,Ramachandra Venkateswari,Pradhabane Gunavathy,Mani Balasundaram Revathi,VN Azger Dusthackeer,Muthaiah Muthuraj
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Singh, N., Singh, P. K., Singh, U., Garg, R. & Jain, A. Fluroquinolone drug resistance among MDR-TB patients increases the risk of unfavourable interim microbiological treatment outcome: An observational study. J. Glob. Antimicrob. Resist. 24, 40–44 (2021).
2. Ho, J., Jelfs, P. & Sintchenko, V. Fluoroquinolone resistance in non-multidrug-resistant tuberculosis—a surveillance study in New South Wales, Australia, and a review of global resistance rates. Int. J. Infect. Dis. 26, 149–153 (2014).
3. Lee, H.-W. & Yim, J.-J. Fluoroquinolone resistance in multidrug-resistant tuberculosis patients. Korean J. Intern. Med. 34, 286–287 (2019).
4. Sharma, R., Singh, B. K., Kumar, P., Ramachandran, R. & Jorwal, P. Presence of Fluoroquinolone mono-resistance among drug-sensitive Mycobacterium tuberculosis isolates: An alarming trend and implications. CEGH 7, 363–366 (2019).
5. Prasad, J., Kumar, P. & Ramachandran, R. Report of the First National Anti-Tuberculosis Drug Resistance Survey India: 2014–2016: Revised National TB Control Programme (2018). https://tbcindia.mohfw.gov.in.